Loading...

Pantuck Allan

TitleAssociate Professor
InstitutionUniversity of California Los Angeles
DepartmentUrology
Address924 Westwood
Suite 1050
Los Angeles CA 90095
Phone(310) 206-2436
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Genetic and molecular characterization of kidney cancer
    NIH/NCI K23CA095151Sep 23, 2002 - Aug 31, 2006
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Upfill-Brown A, Lenis AT, Faiena I, Salmasi AH, Johnson DC, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelines. World J Urol. 2018 Sep 28. PMID: 30267197.
      View in: PubMed
    2. Salmasi A, Faiena I, Lenis AT, Pooli A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma. Urol Oncol. 2018 Sep 15. PMID: 30228094.
      View in: PubMed
    3. Pantuck A, Johnson DC. Editorial comment on END-2018-0144-OR.R1. J Endourol. 2018 Sep 10. PMID: 30200775.
      View in: PubMed
    4. Steven A, Leisz S, Fussek S, Nowroozizadeh B, Huang J, Branstetter D, Dougall WC, Burchardt M, Belldegrun AS, Seliger B, Pantuck A, Kroeger N. Receptor activator of NF-?B (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. Urol Oncol. 2018 Aug 28. PMID: 30170981.
      View in: PubMed
    5. Young JR, Coy H, Kim HJ, Douek M, Sisk A, Pantuck AJ, Raman SS. Clear cell renal cell carcinoma: identifying PTEN expression on multiphasic MDCT. Abdom Radiol (NY). 2018 Jun 27. PMID: 29946925.
      View in: PubMed
    6. Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol. 2018 Jun 01. PMID: 29858701.
      View in: PubMed
    7. McClure T, Pantuck A, Sayer J, Raman S. Efficacy of percutaneous radiofrequency ablation may vary with clear cell renal cell cancer histologic subtype. Abdom Radiol (NY). 2018 Jun; 43(6):1472-1477. PMID: 28936542.
      View in: PubMed
    8. Faiena I, Salmasi A, Mendhiratta N, Lenis AT, Pooli A, Drakaki A, Gollapudi K, Blumberg J, Pantuck AJ, Chamie K. Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapy. World J Urol. 2018 May 11. PMID: 29752514.
      View in: PubMed
    9. Koutsioumpa M, Chen HW, O'Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A. MKAD-21 suppresses the oncogenic activity of the miR-21/PPP2R2A/ERK molecular network in bladder cancer. Mol Cancer Ther. 2018 Apr 27. PMID: 29703843.
      View in: PubMed
    10. Young JR, Coy H, Kim HJ, Douek M, Sisk A, Belldegrun A, Pantuck AJ, Raman SS. Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression. Abdom Radiol (NY). 2018 Mar 08. PMID: 29520426.
      View in: PubMed
    11. Salmasi A, Faiena I, Drakaki A, Pantuck AJ. Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy. Eur Urol. 2018 Feb 09. PMID: 29433972.
      View in: PubMed
    12. Faiena I, Salmasi A, Pantuck AJ, Drakaki A. Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. Eur Urol. 2018 Feb 09. PMID: 29433974.
      View in: PubMed
    13. George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. Clin Cancer Res. 2018 Apr 01; 24(7):1554-1561. PMID: 29374054.
      View in: PubMed
    14. Faiena I, Cummings AL, Crosetti AM, Pantuck AJ, Chamie K, Drakaki A. Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Des Devel Ther. 2018; 12:209-215. PMID: 29416316.
      View in: PubMed
    15. Bachour K, Faiena I, Salmasi A, Lenis AT, Johnson DC, Pooli A, Drakaki A, Pantuck AJ, Chamie K. Trends in urinary diversion after radical cystectomy for urothelial carcinoma. World J Urol. 2018 Mar; 36(3):409-416. PMID: 29299664.
      View in: PubMed
    16. Lenis AT, Salmasi AH, Donin NM, Faiena I, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun AS, Pantuck AJ, Chamie K. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urol Oncol. 2018 Feb; 36(2):78.e21-78.e28. PMID: 29128421.
      View in: PubMed
    17. Liu ST, Hui G, Mathis C, Chamie K, Pantuck AJ, Drakaki A. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era. Clin Genitourin Cancer. 2018 Apr; 16(2):e269-e276. PMID: 29199023.
      View in: PubMed
    18. Faiena I, Salmasi A, Lenis AT, Donin NM, Johnson DC, Bachour K, Drakaki A, Belldegrun AS, Pantuck AJ, Chamie K. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. Urol Oncol. 2018 Feb; 36(2):79.e19-79.e26. PMID: 29103965.
      View in: PubMed
    19. Wang M, Lomeli SH, Franklin WA, Lee S, Pantuck AJ, Zeng G. Optimizing peptide epitope-based autoantibody detection in cancer patients. Am J Clin Exp Immunol. 2017; 6(5):84-91. PMID: 29181273.
      View in: PubMed
    20. Alle N, Tan N, Huss J, Huang J, Pantuck A, Raman SS. Percutaneous image-guided core biopsy of solid renal masses: analysis of safety, efficacy, pathologic interpretation, and clinical significance. Abdom Radiol (NY). 2017 Oct 27. PMID: 29079986.
      View in: PubMed
    21. Lenis AT, Donin NM, Faiena I, Salmasi A, Johnson DC, Drakaki A, Gollapudi K, Blumberg J, Belldegrun A, Pantuck A, Chamie K. Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol. 2018 Jan; 36(1):9.e1-9.e9. PMID: 29066013.
      View in: PubMed
    22. Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. 2018 Jan; 73(1):62-68. PMID: 28967554.
      View in: PubMed
    23. Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017 Jul 01; 3(7):913-920. PMID: 27787547.
      View in: PubMed
    24. Young JR, Coy H, Douek M, Lo P, Sayre J, Pantuck AJ, Raman SS. Type 1 papillary renal cell carcinoma: differentiation from Type 2 papillary RCC on multiphasic MDCT. Abdom Radiol (NY). 2017 Jul; 42(7):1911-1918. PMID: 28265706.
      View in: PubMed
    25. Jones TA, Chin J, Mcleod D, Barkin J, Pantuck A, Marks LS. High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial. J Urol. 2018 Jan; 199(1):133-139. PMID: 28652121.
      View in: PubMed
    26. Casuscelli J, Weinhold N, Gundem G, Wang L, Zabor EC, Drill E, Wang PI, Nanjangud GJ, Redzematovic A, Nargund AM, Manley BJ, Arcila ME, Donin NM, Cheville JC, Thompson RH, Pantuck AJ, Russo P, Cheng EH, Lee W, Tickoo SK, Ostrovnaya I, Creighton CJ, Papaemmanuil E, Seshan VE, Hakimi AA, Hsieh JJ. Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma. JCI Insight. 2017 Jun 15; 2(12). PMID: 28614790.
      View in: PubMed
    27. Young JR, Young JA, Margolis DJA, Sauk S, Sayre J, Pantuck AJ, Raman SS. Sarcomatoid Renal Cell Carcinoma and Collecting Duct Carcinoma: Discrimination From Common Renal Cell Carcinoma Subtypes and Benign RCC Mimics on Multiphasic MDCT. Acad Radiol. 2017 Oct; 24(10):1226-1232. PMID: 28528853.
      View in: PubMed
    28. Young JR, Coy H, Douek M, Lo P, Sayre J, Pantuck AJ, Raman SS. Clear Cell Renal Cell Carcinoma: Identifying the Loss of the Y Chromosome on Multiphasic MDCT. AJR Am J Roentgenol. 2017 Aug; 209(2):333-338. PMID: 28504543.
      View in: PubMed
    29. Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. J Urol. 2018 Jan; 199(1):43-52. PMID: 28479237.
      View in: PubMed
    30. Natarajan S, Jones TA, Priester AM, Geoghegan R, Lieu P, Delfin M, Felker E, Margolis DJA, Sisk A, Pantuck A, Grundfest W, Marks LS. Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance. J Urol. 2017 Oct; 198(4):839-847. PMID: 28396184.
      View in: PubMed
    31. Young JR, Coy H, Kim HJ, Douek M, Lo P, Pantuck AJ, Raman SS. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma. AJR Am J Roentgenol. 2017 Apr; 208(4):812-819. PMID: 28125273.
      View in: PubMed
    32. Donin NM, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Lenis AT, Holden S, Pantuck AJ, Belldegrun AS, Chamie K. Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility. Urol Oncol. 2017 05; 35(5):272-278. PMID: 28065395.
      View in: PubMed
    33. Young JR, Coy H, Douek M, Lo P, Sayre J, Pantuck AJ, Raman SS. Clear cell renal cell carcinoma: identifying the gain of chromosome 12 on multiphasic MDCT. Abdom Radiol (NY). 2017 Jan; 42(1):236-241. PMID: 27519835.
      View in: PubMed
    34. Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, Park SJ, Marks L, Pantuck A, Steinberg M, Kamrava M. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):299-305. PMID: 27965117.
      View in: PubMed
    35. Rini BI, McDermott DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA, Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother Cancer. 2016; 4:81. PMID: 27891227.
      View in: PubMed
    36. Young JR, Young JA, Margolis DJ, Sauk S, Pantuck AJ, Sayre J, Raman SS. Clear cell renal cell carcinoma: identifying the gain of chromosome 20 on multiphasic MDCT. Abdom Radiol (NY). 2016 Nov; 41(11):2175-2181. PMID: 27315079.
      View in: PubMed
    37. Donin NM, Chamie K, Lenis AT, Pantuck AJ, Reddy M, Kivlin D, Holldack J, Pozzi R, Hakim G, Karsh LI, Lamm DL, Belkoff LH, Belldegrun AS, Holden S, Shore N. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol. 2017 02; 35(2):39.e1-39.e7. PMID: 28341495.
      View in: PubMed
    38. Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DYC. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol. 2017 06; 71(6):970-978. PMID: 27771126.
      View in: PubMed
    39. Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ. Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. N Engl J Med. 2016 12 08; 375(23):2246-2254. PMID: 27718781.
      View in: PubMed
    40. Donin NM, Duarte S, Lenis AT, Caliliw R, Torres C, Smithson A, Strauss-Ayali D, Agmon-Gerstein Y, Malchi N, Said J, Raman SS, Holden S, Pantuck A, Belldegrun AS, Chamie K. Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. Urology. 2017 Jan; 99:270-277. PMID: 27720772.
      View in: PubMed
    41. Donin NM, Lenis AT, Holden S, Drakaki A, Pantuck A, Belldegrun A, Chamie K. Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol. 2017 Jan; 197(1):14-22. PMID: 27460757.
      View in: PubMed
    42. Donin NM, Pantuck A, Klöpfer P, Bevan P, Fall B, Said J, Belldegrun AS, Chamie K. Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma. Cancer Epidemiol Biomarkers Prev. 2016 09; 25(9):1326-32. PMID: 27418270.
      View in: PubMed
    43. Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proc Natl Acad Sci U S A. 2016 Feb 23; 113(8):2170-5. PMID: 26864202; PMCID: PMC4776463.
    44. Weight CJ, Mulders PF, Pantuck AJ, Thompson RH. The Role of Adrenalectomy in Renal Cancer. Eur Urol Focus. 2016 Feb; 1(3):251-257. PMID: 28723393.
      View in: PubMed
    45. Miles FL, Rao JY, Eckhert C, Chang SC, Pantuck A, Zhang ZF. Associations of immunity-related single nucleotide polymorphisms with overall survival among prostate cancer patients. Int J Clin Exp Med. 2015; 8(7):11470-6. PMID: 26379965; PMCID: PMC4565348.
    46. Kroeger N, Zimmermann U, Burchardt M, Pantuck AJ. Prognostication in localised renal cell carcinoma. Lancet Oncol. 2015 Jun; 16(6):603-4. PMID: 25979596.
      View in: PubMed
    47. An J, Guo Y, Wang T, Pantuck AJ, Rettig MB. Pomegranate extract inhibits EMT in clear cell renal cell carcinoma in a NF-?B and JNK dependent manner. Asian J Urol. 2015 Jan; 2(1):38-45. PMID: 29264118.
      View in: PubMed
    48. Chamie K, Klöpfer P, Bevan P, Störkel S, Said J, Fall B, Belldegrun AS, Pantuck AJ. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. Urol Oncol. 2015 May; 33(5):204.e25-33. PMID: 25823535.
      View in: PubMed
    49. Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. Eur Urol. 2015 Sep; 68(3):506-15. PMID: 25524810.
      View in: PubMed
    50. McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015 Feb 01; 21(3):561-8. PMID: 25424850; PMCID: PMC4315731.
    51. Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, Shariat SF, Belldegrun AS, Klatte T. The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. Urol Oncol. 2015 Feb; 33(2):68.e1-7. PMID: 25240758.
      View in: PubMed
    52. McClure TD, Chow DS, Tan N, Sayre JA, Pantuck AJ, Raman SS. Intermediate outcomes and predictors of efficacy in the radiofrequency ablation of 100 pathologically proven renal cell carcinomas. J Vasc Interv Radiol. 2014 Nov; 25(11):1682-8; quiz 1689. PMID: 25081202.
      View in: PubMed
    53. Pignot G, Bigot P, Bernhard JC, Bouliere F, Bessede T, Bensalah K, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Drai J, Colombel M, Villers A, Rigaud J, Bouchot O, Montorsi F, Bertini R, Belldegrun AS, Pantuck AJ, Patard JJ. Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff. Urol Oncol. 2014 Oct; 32(7):1024-30. PMID: 24996775.
      View in: PubMed
    54. Kroeger N, Pantuck AJ. Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.007. Eur Urol. 2014 Oct; 66(4):e69-70. PMID: 24973996.
      View in: PubMed
    55. Kroeger N, Belldegrun AS, Pantuck AJ. The contemporary role on surgery in the management of renal masses. World J Urol. 2014 Jun; 32(3):571-2. PMID: 24718636.
      View in: PubMed
    56. Young JR, Margolis D, Sauk S, Pantuck AJ, Sayre J, Young JA, Hsu M, Raman SS. Clear cell renal cell carcinoma: multiphasic MDCT enhancement can predict the loss of chromosome 8p. Abdom Imaging. 2014 Jun; 39(3):543-9. PMID: 24573763.
      View in: PubMed
    57. Klatte T, Kroeger N, Zimmermann U, Burchardt M, Belldegrun AS, Pantuck AJ. The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation. World J Urol. 2014 Jun; 32(3):597-605. PMID: 24700308.
      View in: PubMed
    58. Kroeger N, Seligson DB, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS, Pantuck AJ. Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2a. Eur J Cancer. 2014 May; 50(8):1531-40. PMID: 24565854.
      View in: PubMed
    59. Freedland SJ, Carducci M, Kroeger N, Partin A, Rao JY, Jin Y, Kerkoutian S, Wu H, Li Y, Creel P, Mundy K, Gurganus R, Fedor H, King SA, Zhang Y, Heber D, Pantuck AJ. A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. Cancer Prev Res (Phila). 2013 Oct; 6(10):1120-7. PMID: 23985577; PMCID: PMC3806642.
    60. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, Klatte T. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013 Dec; 190(6):1999-2004. PMID: 23831313.
      View in: PubMed
    61. Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J. 2013 May-Jun; 19(3):189-96. PMID: 23708063.
      View in: PubMed
    62. Rampersaud EN, Klatte T, Bass G, Patard JJ, Bensaleh K, Böhm M, Allhoff EP, Cindolo L, De La Taille A, Mejean A, Soulie M, Bellec L, Christophe Bernhard J, Pfister C, Colombel M, Belldegrun AS, Pantuck AJ, George D. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol. 2014 Jan; 32(1):30.e9-13. PMID: 23422777.
      View in: PubMed
    63. Young JR, Margolis D, Sauk S, Pantuck AJ, Sayre J, Raman SS. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT. Radiology. 2013 May; 267(2):444-53. PMID: 23382290.
      View in: PubMed
    64. Birkhäuser FD, Koya RC, Neufeld C, Rampersaud EN, Lu X, Micewicz ED, Chodon T, Atefi M, Kroeger N, Chandramouli GV, Li G, Said JW, McBride WH, Kabbinavar FF, Ribas A, Pantuck AJ, Belldegrun AS, Riss J. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J Immunother. 2013 Feb; 36(2):102-11. PMID: 23377663.
      View in: PubMed
    65. Kroeger N, Klatte T, Chamie K, Rao PN, Birkhäuser FD, Sonn GA, Riss J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma. Cancer. 2013 Apr 15; 119(8):1547-54. PMID: 23335244.
      View in: PubMed
    66. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. PMID: 23228172; PMCID: PMC3683570.
    67. Seligson DB, Yu H, Tze S, Said J, Pantuck AJ, Cohen P, Lee KW. IGFBP-3 nuclear localization predicts human prostate cancer recurrence. Horm Cancer. 2013 Feb; 4(1):12-23. PMID: 23011725; PMCID: PMC3541441.
    68. Heesakkers J, Farag F, Pantuck A, Moore K, Radziszewski P, Lucas M. Applicability of a disposable home urinary flow measuring device as a diagnostic tool in the management of males with lower urinary tract symptoms. Urol Int. 2012; 89(2):166-72. PMID: 22797567.
      View in: PubMed
    69. Klatte T, Kroeger N, Rampersaud EN, Birkhäuser FD, Logan JE, Sonn G, Riss J, Rao PN, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma. Cancer. 2012 Dec 01; 118(23):5777-82. PMID: 22605478.
      View in: PubMed
    70. Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. Eur Urol. 2012 May; 61(5):888-95. PMID: 22269604.
      View in: PubMed
    71. Shuch B, Bratslavsky G, Shih J, Vourganti S, Finley D, Castor B, Treat E, Linehan WM, Pantuck AJ, Said JW, Belldegrun AS. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 2012 Jun; 109(11):1600-6. PMID: 22221668.
      View in: PubMed
    72. Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012; 14(3-4):65-78. PMID: 23526579; PMCID: PMC3602729.
    73. Kroeger N, Rampersaud EN, Patard JJ, Klatte T, Birkhäuser FD, Shariat SF, Lang H, Rioux-Leclerq N, Remzi M, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol. 2012 Feb; 187(2):418-23. PMID: 22177164.
      View in: PubMed
    74. Sauk SC, Hsu MS, Margolis DJ, Lu DS, Rao NP, Belldegrun AS, Pantuck AJ, Raman SS. Clear cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic karyotypes. Radiology. 2011 Dec; 261(3):854-62. PMID: 22025734.
      View in: PubMed
    75. Finley DS, Shuch B, Said JW, Galliano G, Jeffries RA, Afifi AA, Castor B, Magyar C, Sadaat A, Kabbinavar FF, Belldegrun AS, Pantuck AJ. The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. J Urol. 2011 Dec; 186(6):2168-74. PMID: 22014797.
      View in: PubMed
    76. Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer. 2012 Apr 01; 118(7):1795-802. PMID: 21997347.
      View in: PubMed
    77. Hall SJ, Klotz L, Pantuck AJ, George DJ, Whitmore JB, Frohlich MW, Sims RB. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011 Sep; 186(3):877-81. PMID: 21788048.
      View in: PubMed
    78. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011 Oct; 60(4):644-61. PMID: 21741163.
      View in: PubMed
    79. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011 Apr 19; 9:43. PMID: 21504557; PMCID: PMC3102624.
    80. Pouliot F, Pantuck A, Imbeault A, Shuch B, Calimlim B, Audet JF, Finley DS, Dujardin T. Multivariate analysis of the factors involved in loss of renal differential function after laparoscopic partial nephrectomy: a role for warm ischemia time. Can Urol Assoc J. 2011 Apr; 5(2):89-95. PMID: 21470531; PMCID: PMC3104439.
    81. Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int. 2011 Mar; 107(5):724-728. PMID: 20626391.
      View in: PubMed
    82. Mohler JL, Pantuck AJ. Use of abiraterone for prostate cancer. J Urol. 2011 Mar; 185(3):783-6. PMID: 21239011.
      View in: PubMed
    83. Finley DS, Pantuck AJ, Belldegrun AS. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist. 2011; 16 Suppl 2:4-13. PMID: 21346035; PMCID: PMC3868202.
    84. Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, Saigal C. Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance. BJU Int. 2011 Aug; 108(3):343-8. PMID: 21087450.
      View in: PubMed
    85. Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol. 2011 Jan; 185(1):30-5. PMID: 21074210.
      View in: PubMed
    86. Oh SS, Chang SC, Cai L, Cordon-Cardo C, Ding BG, Greenland S, He N, Jiang Q, Kheifets L, Le A, Lee YC, Liu S, Lu ML, Mao JT, Morgenstern H, Mu LN, Pantuck A, Papp JC, Park SL, Rao JY, Reuter VE, Tashkin DP, Wang H, You NC, Yu SZ, Zhao JK, Belldegrun A, Zhang ZF. Single nucleotide polymorphisms of 8 inflammation-related genes and their associations with smoking-related cancers. Int J Cancer. 2010 Nov 01; 127(9):2169-82. PMID: 20112337; PMCID: PMC2932751.
    87. La Rochelle J, Klatte T, Dastane A, Rao N, Seligson D, Said J, Shuch B, Zomorodian N, Kabbinavar F, Belldegrun A, Pantuck AJ. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer. 2010 Oct 15; 116(20):4696-702. PMID: 20629029.
      View in: PubMed
    88. Finley DS, Pouliot F, Pantuck A. Words of wisdom. Re: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Eur Urol. 2010 Sep; 58(3):466. PMID: 20845530.
      View in: PubMed
    89. Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS. Contemporary management of renal tumors with venous tumor thrombus. J Urol. 2010 Sep; 184(3):833-41; quiz 1235. PMID: 20643450.
      View in: PubMed
    90. Klatte T, Anterasian C, Said JW, de Martino M, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. J Urol. 2010 Jun; 183(6):2143-7. PMID: 20399450.
      View in: PubMed
    91. Zisman A, Patard JJ, Raz O, Klatte T, Haifler M, Mendlovic S, Sandbank J, Belldegrun AS, Lindner A, Leibovici D, Pantuck AJ. Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology. 2010 Sep; 76(3):541-6. PMID: 20494411.
      View in: PubMed
    92. Park SL, Bastani D, Goldstein BY, Chang SC, Cozen W, Cai L, Cordon-Cardo C, Ding B, Greenland S, He N, Hussain SK, Jiang Q, Lee YC, Liu S, Lu ML, Mack TM, Mao JT, Morgenstern H, Mu LN, Oh SS, Pantuck A, Papp JC, Rao J, Reuter VE, Tashkin DP, Wang H, You NC, Yu SZ, Zhao JK, Zhang ZF. Associations between NBS1 polymorphisms, haplotypes and smoking-related cancers. Carcinogenesis. 2010 Jul; 31(7):1264-71. PMID: 20478923; PMCID: PMC2893801.
    93. Klatte T, Remzi M, Zigeuner RE, Mannweiler S, Said JW, Kabbinavar FF, Haitel A, Waldert M, de Martino M, Marberger M, Belldegrun AS, Pantuck AJ. Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. J Urol. 2010 Jul; 184(1):53-8. PMID: 20478577.
      View in: PubMed
    94. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Garraway I, Wong SG, Belldegrun AS, Pantuck AJ. Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. J Urol. 2010 Jun; 183(6):2403-8. PMID: 20403620.
      View in: PubMed
    95. Bernhard JC, Pantuck AJ, Wallerand H, Crepel M, Ferrière JM, Bellec L, Maurice-Tison S, Robert G, Albouy B, Pasticier G, Soulie M, Lopes D, Lacroix B, Bensalah K, Pfister C, Thuret R, Tostain J, De La Taille A, Salomon L, Abbou C, Colombel M, Belldegrun AS, Patard JJ. Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma. Eur Urol. 2010 Jun; 57(6):1080-6. PMID: 20188458.
      View in: PubMed
    96. Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer. 2010 Feb 01; 116(3):616-24. PMID: 19998348; PMCID: PMC3162346.
    97. Pantuck AJ. Editorial comment. J Urol. 2010 Mar; 183(3):914. PMID: 20083263.
      View in: PubMed
    98. Pantuck AJ, An J, Liu H, Rettig MB. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res. 2010 Jan 15; 70(2):752-61. PMID: 20068166.
      View in: PubMed
    99. Pantuck AJ. Editorial comment. J Urol. 2010 Jan; 183(1):41-2. PMID: 19913244.
      View in: PubMed
    100. Koyama S, Cobb LJ, Mehta HH, Seeram NP, Heber D, Pantuck AJ, Cohen P. Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res. 2010 Feb; 20(1):55-62. PMID: 19853487; PMCID: PMC2815223.
    101. Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrun AS, Zini L, de la Taille A, Chautard D, Descotes JL, Shariat SF, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ. Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol. 2009 Dec; 182(6):2607-12. PMID: 19836798.
      View in: PubMed
    102. Shuch B, Said J, La Rochelle JC, Zhou Y, Li G, Klatte T, Kabbinaavar FF, Pantuck AJ, Belldegrun AS. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol. 2009 Nov; 182(5):2164-71. PMID: 19758641; PMCID: PMC3175230.
    103. de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF, Pantuck AJ, Belldegrun AS. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol. 2009 Aug; 182(2):728-34. PMID: 19539328.
      View in: PubMed
    104. Pouliot F, Pantuck AJ. Words of wisdom. Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo- controlled phase III trial. Eur Urol. 2009 Jun; 55(6):1482-4. PMID: 19650239.
      View in: PubMed
    105. Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ. Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker. Cancer. 2009 Apr 01; 115(7):1448-58. PMID: 19195047.
      View in: PubMed
    106. Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, Mottet N, Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P, De la Taille A, Avakian R, Crepel M, Ferriere JM, Bernhard JC, Dujardin T, Pouliot F, Rigaud J, Pfister C, Albouy B, Guy L, Joniau S, van Poppel H, Lebret T, Culty T, Saint F, Zisman A, Raz O, Lang H, Spie R, Wille A, Roigas J, Aguilera A, Rambeaud B, Martinez Piñeiro L, Nativ O, Farfara R, Richard F, Roupret M, Doehn C, Bastian PJ, Muller SC, Tostain J, Belldegrun AS, Patard JJ. Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol. 2010 Mar; 57(3):466-71. PMID: 19359089.
      View in: PubMed
    107. La Rochelle J, Shuch B, Riggs S, Liang LJ, Saadat A, Kabbinavar F, Pantuck A, Belldegrun A. Functional and oncological outcomes of partial nephrectomy of solitary kidneys. J Urol. 2009 May; 181(5):2037-42; discussion 2043. PMID: 19298974.
      View in: PubMed
    108. Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):894-900. PMID: 19240241.
      View in: PubMed
    109. Klatte T, Said JW, de Martino M, Larochelle J, Shuch B, Rao JY, Thomas GV, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. J Urol. 2009 Apr; 181(4):1558-64; discussion 1563-4. PMID: 19230920.
      View in: PubMed
    110. Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009 Feb 15; 15(4):1162-9. PMID: 19228721.
      View in: PubMed
    111. Klatte T, Rao PN, de Martino M, LaRochelle J, Shuch B, Zomorodian N, Said J, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009 Feb 10; 27(5):746-53. PMID: 19124809.
      View in: PubMed
    112. Shuch B, Larochelle JC, Onyia T, Vallera C, Margulis D, Pantuck AJ, Smith RB, Belldegrun AS. Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol. 2009 Feb; 181(2):492-8; discussion 498-9. PMID: 19110280.
      View in: PubMed
    113. Park SL, Chang SC, Cai L, Cordon-Cardo C, Ding BG, Greenland S, Hussain SK, Jiang Q, Liu S, Lu ML, Mao JT, Morgenstern H, Mu LN, Ng LJ, Pantuck A, Rao J, Reuter VE, Tashkin DP, You NC, Yu CQ, Yu SZ, Zhao JK, Belldegrun A, Zhang ZF. Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17(11):3193-202. PMID: 18990762; PMCID: PMC2664075.
    114. Klatte T, Pantuck AJ. Molecular biology of renal cortical tumors. Urol Clin North Am. 2008 Nov; 35(4):573-80; vi. PMID: 18992611.
      View in: PubMed
    115. Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer. 2008 Nov 01; 113(9):2457-63. PMID: 18823034.
      View in: PubMed
    116. La Rochelle J, Kamat A, Grossman HB, Pantuck A. Chemoprevention of bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1274-8. PMID: 19035892.
      View in: PubMed
    117. Shuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer. 2008 Oct 01; 113(7):1641-8. PMID: 18671240.
      View in: PubMed
    118. Shuch B, La Rochelle JC, Wu J, Klatte T, Riggs SB, Kabbinavar F, Belldegrun AS, Pantuck AJ. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer. 2008 Sep 15; 113(6):1324-31. PMID: 18661529.
      View in: PubMed
    119. Shuch B, La Rochelle JC, Pantuck AJ, Belldegrun AS. The staging of renal cell carcinoma. Curr Opin Urol. 2008 Sep; 18(5):455-61. PMID: 18670267.
      View in: PubMed
    120. Rettig MB, Heber D, An J, Seeram NP, Rao JY, Liu H, Klatte T, Belldegrun A, Moro A, Henning SM, Mo D, Aronson WJ, Pantuck A. Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. Mol Cancer Ther. 2008 Sep; 7(9):2662-71. PMID: 18790748; PMCID: PMC2858627.
    121. Bensalah K, Pantuck AJ, Crepel M, Verhoest G, Méjean A, Valéri A, Ficarra V, Pfister C, Ferrière JM, Soulié M, Cindolo L, De La Taille A, Tostain J, Chautard D, Schips L, Zigeuner R, Abbou CC, Lobel B, Salomon L, Lechevallier E, Descotes JL, Guillé F, Colombel M, Belldegrun AS, Patard JJ. Prognostic variables to predict cancer-related death in incidental renal tumours. BJU Int. 2008 Nov; 102(10):1376-80. PMID: 18727618.
      View in: PubMed
    122. Patard JJ, Fergelot P, Karakiewicz PI, Klatte T, Trinh QD, Rioux-Leclercq N, Said JW, Belldegrun AS, Pantuck AJ. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008 Jul 15; 123(2):395-400. PMID: 18464292; PMCID: PMC2721857.
    123. Pantuck AJ, Klatte T, Seligson D, Atkins M, Belldegrun A. Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. J Clin Oncol. 2008 Jun 20; 26(18):3105-7; author reply 3107-9. PMID: 18565906.
      View in: PubMed
    124. Klatte T, Belldegrun AS, Pantuck AJ. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder. BJU Int. 2008 Jun; 101 Suppl 4:45-8. PMID: 18430124.
      View in: PubMed
    125. Shuch B, Riggs SB, LaRochelle JC, Kabbinavar FF, Avakian R, Pantuck AJ, Patard JJ, Belldegrun AS. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int. 2008 Sep; 102(6):692-6. PMID: 18410444.
      View in: PubMed
    126. Klatte T, Patard JJ, de Martino M, Bensalah K, Verhoest G, de la Taille A, Abbou CC, Allhoff EP, Carrieri G, Riggs SB, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol. 2008 May; 179(5):1719-26. PMID: 18343437.
      View in: PubMed
    127. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, Henning SM, Firouzi A, Rettig MB, Aronson WJ, Pantuck AJ, Heber D. Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol. 2008 Feb; 32(2):475-80. PMID: 18202771.
      View in: PubMed
    128. Klatte T, Han KR, Said JW, Böhm M, Allhoff EP, Kabbinavar FF, Belldegrun AS, Pantuck AJ. Pathobiology and prognosis of chromophobe renal cell carcinoma. Urol Oncol. 2008 Nov-Dec; 26(6):604-9. PMID: 18367104.
      View in: PubMed
    129. Jones J, Pantuck AJ. Genomics and proteomics in renal cell carcinoma: diagnosis, prognosis, and treatment selection. Curr Urol Rep. 2008 Jan; 9(1):9-14. PMID: 18366968.
      View in: PubMed
    130. Shi R, Xie Q, Gang X, Lun J, Cheng L, Pantuck A, Rao J. Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. J Urol. 2008 Feb; 179(2):610-5. PMID: 18082217.
      View in: PubMed
    131. Jones J, Otu HH, Grall F, Spentzos D, Can H, Aivado M, Belldegrun AS, Pantuck AJ, Libermann TA. Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. J Urol. 2008 Feb; 179(2):730-6. PMID: 18082202; PMCID: PMC3836557.
    132. Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res. 2007 Dec 15; 13(24):7388-93. PMID: 18094421.
      View in: PubMed
    133. Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ. Surveillance for renal cell carcinoma: why and how? When and how often? Urol Oncol. 2008 Sep-Oct; 26(5):550-4. PMID: 18774472.
      View in: PubMed
    134. Hutterer GC, Patard JJ, Colombel M, Belldegrun AS, Pfister C, Guille F, Artibani W, Montorsi F, Pantuck AJ, Karakiewicz PI. Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma. Cancer. 2007 Dec 01; 110(11):2428-33. PMID: 17941033.
      View in: PubMed
    135. Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol. 2008 Jan; 179(1):61-6. PMID: 17997430.
      View in: PubMed
    136. Pantuck AJ, Baniel J, Kirkali Z, Klatte T, Zomorodian N, Yossepowitch O, Belldegrun AS. A novel resectoscope for transurethral resection of bladder tumors and the prostate. J Urol. 2007 Dec; 178(6):2331-6; discussion 2336. PMID: 17936809.
      View in: PubMed
    137. Lam JS, Klatte T, Kim HL, Patard JJ, Breda A, Zisman A, Pantuck AJ, Figlin RA. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol. 2008 Mar; 65(3):235-62. PMID: 17931881.
      View in: PubMed
    138. Karakiewicz PI, Hutterer GC, Trinh QD, Pantuck AJ, Klatte T, Lam JS, Guille F, de La Taille A, Novara G, Tostain J, Cindolo L, Ficarra V, Schips L, Zigeuner R, Mulders PF, Chautard D, Lechevallier E, Valeri A, Descotes JL, Lang H, Soulie M, Ferriere JM, Pfister C, Mejean A, Belldegrun AS, Patard JJ. Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int. 2007 Oct; 100(4):802-8. PMID: 17822461.
      View in: PubMed
    139. Pantuck AJ. Editorial comment on: Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol. 2007 Oct; 52(4):1145-6. PMID: 17336450.
      View in: PubMed
    140. Raz O, Mendlovic S, Leibovici D, Pantuck AJ, Sandbank J, Sella A, Lindner A, Zisman A. The prevalence of malignancy in satellite renal lesions and its surgical implication during nephron sparing surgery. J Urol. 2007 Nov; 178(5):1892-5; discussion 1895. PMID: 17868730.
      View in: PubMed
    141. Gulati M, Gore JL, Pantuck AJ, Kim Y, Barajas L, Rajfer J. Ureteral tumor thrombus from renal cell carcinoma extending into bladder. Urol Oncol. 2007 Sep-Oct; 25(5):393-5. PMID: 17826656.
      View in: PubMed
    142. Seeram NP, Aronson WJ, Zhang Y, Henning SM, Moro A, Lee RP, Sartippour M, Harris DM, Rettig M, Suchard MA, Pantuck AJ, Belldegrun A, Heber D. Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem. 2007 Sep 19; 55(19):7732-7. PMID: 17722872.
      View in: PubMed
    143. Klatte T, Pantuck AJ, Riggs SB, Kleid MD, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS. Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol. 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PMID: 17698087.
      View in: PubMed
    144. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007 Jul 27; 7:142. PMID: 17662137; PMCID: PMC1941739.
    145. Klatte T, Said JW, Belldegrun AS, Pantuck AJ. Differential diagnosis of hypercalcemia in renal malignancy. Urology. 2007 Jul; 70(1):179.e7-8. PMID: 17656242.
      View in: PubMed
    146. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer. 2007 Jun 01; 109(11):2257-67. PMID: 17440983.
      View in: PubMed
    147. Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol. 2007 Jun; 177(6):2081-6; discussion 2086-7. PMID: 17509291.
      View in: PubMed
    148. Klatte T, Patard JJ, Goel RH, Kleid MD, Guille F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Allhoff EP, Schips L, Zigeuner R, Figlin RA, Kabbinavar FF, Pantuck AJ, Belldegrun AS, Lam JS. Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol. 2007 Jul; 178(1):35-40; discussion 40. PMID: 17521678.
      View in: PubMed
    149. Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM. Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy. J Immunother. 2007 May-Jun; 30(4):417-24. PMID: 17457216.
      View in: PubMed
    150. Klatte T, Rao JY, Ribas A, Pantuck AJ. Metastatic melanoma to the kidney presenting with renal vein tumor thrombus. Urology. 2007 May; 69(5):982.e7-9. PMID: 17482952.
      View in: PubMed
    151. Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. The role of molecular markers in the staging of renal cell carcinoma. BJU Int. 2007 May; 99(5 Pt B):1208-11. PMID: 17441912.
      View in: PubMed
    152. Klatte T, Wunderlich H, Patard JJ, Kleid MD, Lam JS, Junker K, Schubert J, Böhm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int. 2007 Jul; 100(1):21-5. PMID: 17433034.
      View in: PubMed
    153. Karakiewicz PI, Trinh QD, Lam JS, Tostain J, Pantuck AJ, Belldegrun AS, Patard JJ. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol. 2007 Nov; 52(5):1428-36. PMID: 17420085.
      View in: PubMed
    154. Lam JS, Klatte T, Patard JJ, Goel RH, Guillè F, Lobel B, Abbou CC, De La Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Artibani W, Prayer-Galetti T, Schips L, Zigeuner R, Pantuck AJ, Figlin RA, Belldegrun AS. Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur Urol. 2007 Jul; 52(1):155-62. PMID: 17316970.
      View in: PubMed
    155. Klatte T, Chung J, Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int. 2007 Apr; 99(4):821-4. PMID: 17244281.
      View in: PubMed
    156. Patard JJ, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, Lopes D, Bernhard JC, Guillé F, Lacroix B, De La Taille A, Salomon L, Pfister C, Soulié M, Tostain J, Ferriere JM, Abbou CC, Colombel M, Belldegrun AS. Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol. 2007 Jul; 52(1):148-54. PMID: 17240036.
      View in: PubMed
    157. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s. PMID: 17255291.
      View in: PubMed
    158. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):703s-708s. PMID: 17255297.
      View in: PubMed
    159. Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):693s-696s. PMID: 17255295.
      View in: PubMed
    160. Pantuck AJ, Zomorodian N, Belldegrun AS. Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy. Curr Urol Rep. 2007 Jan; 8(1):3-4. PMID: 17239310.
      View in: PubMed
    161. Xiao GS, Jin YS, Lu QY, Zhang ZF, Belldegrun A, Figlin R, Pantuck A, Yen Y, Li F, Rao J. Annexin-I as a potential target for green tea extract induced actin remodeling. Int J Cancer. 2007 Jan 01; 120(1):111-20. PMID: 17019707.
      View in: PubMed
    162. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol. 2007; 9(2):47-56. PMID: 17592537; PMCID: PMC1892626.
    163. Leppert JT, Pantuck AJ. Determining the prognosis of patients with renal cell carcinoma: is it time for a re-evaluation? Nat Clin Pract Urol. 2006 Oct; 3(10):510-1. PMID: 17031370.
      View in: PubMed
    164. Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol. 2006 Oct; 33(5):607-13. PMID: 17045090.
      View in: PubMed
    165. Hung RJ, Zhang ZF, Rao JY, Pantuck A, Reuter VE, Heber D, Lu QY. Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol. 2006 Sep; 176(3):1192-7. PMID: 16890724.
      View in: PubMed
    166. Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ, Zeng G, Horvath S, Belldegrun AS. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int. 2006 Aug; 98(2):445-51. PMID: 16879693.
      View in: PubMed
    167. Jin Y, Iwata KK, Belldegrun A, Figlin R, Pantuck A, Zhang ZF, Lieberman R, Rao J. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther. 2006 Jul; 5(7):1754-63. PMID: 16891461.
      View in: PubMed
    168. Pantuck AJ, Leppert JT, Zomorodian N, Aronson W, Hong J, Barnard RJ, Seeram N, Liker H, Wang H, Elashoff R, Heber D, Aviram M, Ignarro L, Belldegrun A. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res. 2006 Jul 01; 12(13):4018-26. PMID: 16818701.
      View in: PubMed
    169. Lam JS, Belldegrun AS, Pantuck AJ. Long-term outcomes of the surgical management of renal cell carcinoma. World J Urol. 2006 Aug; 24(3):255-66. PMID: 16479388.
      View in: PubMed
    170. Leppert JT, Pantuck AJ. Significance of gene expression analysis of renal cell carcinoma. Expert Rev Anticancer Ther. 2006 Feb; 6(2):293-9. PMID: 16445381.
      View in: PubMed
    171. Pantuck AJ, Zomorodian N, Belldegrun AS. Phase-II Study of pomegranate juice for men with prostate cancer and increasing PSA. Curr Urol Rep. 2006 Jan; 7(1):7. PMID: 16480662.
      View in: PubMed
    172. Leppert JT, Shvarts O, Kawaoka K, Lieberman R, Belldegrun AS, Pantuck AJ. Prevention of bladder cancer: a review. Eur Urol. 2006 Feb; 49(2):226-34. PMID: 16413099.
      View in: PubMed
    173. Cao W, Cai L, Rao JY, Pantuck A, Lu ML, Dalbagni G, Reuter V, Scher H, Cordon-Cardo C, Figlin RA, Belldegrun A, Zhang ZF. Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma. Cancer. 2005 Dec 01; 104(11):2400-8. PMID: 16240451.
      View in: PubMed
    174. Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol. 2005 Oct 15; 175(8):5351-7. PMID: 16210641.
      View in: PubMed
    175. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005 Aug 15; 11(16):5730-9. PMID: 16115910.
      View in: PubMed
    176. Lam JS, Shvarts O, Leppert JT, Pantuck AJ, Figlin RA, Belldegrun AS. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005 Aug; 174(2):466-72; discussion 472; quiz 801. PMID: 16006866.
      View in: PubMed
    177. Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int. 2005 Aug; 96(3):281-5. PMID: 16042714.
      View in: PubMed
    178. Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer. 2005 Jun 15; 103(12):2517-25. PMID: 15880379.
      View in: PubMed
    179. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005 Apr 20; 23(12):2763-71. PMID: 15837991.
      View in: PubMed
    180. Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, deKernion JB, Belldegrun AS. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer. 2005 Mar 20; 114(2):268-73. PMID: 15540228.
      View in: PubMed
    181. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep. 2005 Mar; 7(2):109-15. PMID: 15717944.
      View in: PubMed
    182. Shvarts O, Seligson D, Lam J, Shi T, Horvath S, Figlin R, Belldegrun A, Pantuck AJ. p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol. 2005 Mar; 173(3):725-8. PMID: 15711252.
      View in: PubMed
    183. Lu QY, Jin YS, Pantuck A, Zhang ZF, Heber D, Belldegrun A, Brooks M, Figlin R, Rao J. Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res. 2005 Feb 15; 11(4):1675-83. PMID: 15746073.
      View in: PubMed
    184. Patard JJ, Dorey FJ, Cindolo L, Ficarra V, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Belldegrun AS, Pantuck AJ. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol. 2004 Dec; 172(6 Pt 1):2167-71. PMID: 15538224.
      View in: PubMed
    185. Han KR, Janzen NK, McWhorter VC, Kim HL, Pantuck AJ, Zisman A, Figlin RA, Dorey FJ, Said JW, Belldegrun AS. Cystic renal cell carcinoma: biology and clinical behavior. Urol Oncol. 2004 Sep-Oct; 22(5):410-4. PMID: 15464922.
      View in: PubMed
    186. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004 Aug 15; 22(16):3316-22. PMID: 15310775.
      View in: PubMed
    187. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004 Jun; 171(6 Pt 1):2181-5, quiz 2435. PMID: 15126781.
      View in: PubMed
    188. Lam JS, Shvarts O, Pantuck AJ. Changing concepts in the surgical management of renal cell carcinoma. Eur Urol. 2004 Jun; 45(6):692-705. PMID: 15149740.
      View in: PubMed
    189. Han KR, Kim HL, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun AS. Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology. 2004 May; 63(5):841-6; discussion 846-7. PMID: 15134960.
      View in: PubMed
    190. Pantuck AJ, van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J Immunother. 2004 May-Jun; 27(3):240-53. PMID: 15076142.
      View in: PubMed
    191. Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA. Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2659-69. PMID: 15102668.
      View in: PubMed
    192. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Fujioka T, Mori M, Kim WJ, Song JM, Pantuck AJ. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol. 2004 Feb; 34(2):86-9. PMID: 15067102.
      View in: PubMed
    193. Leibovich BC, Han KR, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003 Dec 15; 98(12):2566-75. PMID: 14669275.
      View in: PubMed
    194. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol. 2003 Dec; 170(6 Pt 1):2221-4. PMID: 14634383.
      View in: PubMed
    195. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003 Oct 15; 9(13):4641-52. PMID: 14581333.
      View in: PubMed
    196. Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003 Oct; 170(4 Pt 1):1126-30. PMID: 14501706.
      View in: PubMed
    197. Janzen NK, Laifer-Narin S, Han KR, Seltzer M, Thomas MA, Pantuck AJ, Belldegrun AS. Emerging technologies in uroradiologic imaging. Urol Oncol. 2003 Sep-Oct; 21(5):317-26. PMID: 14670537.
      View in: PubMed
    198. Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS. Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. J Urol. 2003 Sep; 170(3):768-72; discussion 772. PMID: 12913694.
      View in: PubMed
    199. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003 Sep-Oct; 26(5):412-9. PMID: 12973030.
      View in: PubMed
    200. Zisman A, Pantuck AJ, Bui MH, Said JW, Caliliw RR, Rao N, Shintaku P, Berger F, Gambhir SS, Belldegrun AS. LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen. Cancer Res. 2003 Aug 15; 63(16):4952-9. PMID: 12941820.
      View in: PubMed
    201. Leibovich BC, Pantuck AJ, Bui MH, Ryu-Han K, Zisman A, Figlin R, Belldegrun A. Current staging of renal cell carcinoma. Urol Clin North Am. 2003 Aug; 30(3):481-97, viii. PMID: 12953750.
      View in: PubMed
    202. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003 Jun 15; 97(12):2995-3002. PMID: 12784334.
      View in: PubMed
    203. Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system. Prostate. 2003 Jun 01; 55(4):299-307. PMID: 12712409.
      View in: PubMed
    204. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003 Jun; 169(6):2076-83. PMID: 12771723.
      View in: PubMed
    205. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 2003 Apr 01; 55(1):71-80. PMID: 12640663.
      View in: PubMed
    206. Visapää H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, Figlin R, Rao JY, Belldegrun A, Horvath S, Palotie A. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 2003 Apr; 61(4):845-50. PMID: 12670587.
      View in: PubMed
    207. Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin RA, Belldegrun AS. TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion. J Urol. 2003 Mar; 169(3):899-903; discussion 903-4. PMID: 12576809.
      View in: PubMed
    208. Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS. Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol. 2003 Mar; 169(3):909-16. PMID: 12576811.
      View in: PubMed
    209. Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003 Feb; 61(2):314-9. PMID: 12597937.
      View in: PubMed
    210. Kim HL, Pantuck AJ, Zomorodian N, Belldegrun AS. Monoclonal antibody (MAB) in patients with advanced cancer. Curr Urol Rep. 2003 Feb; 4(1):11-2. PMID: 12537933.
      View in: PubMed
    211. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003 Feb; 9(2):802-11. PMID: 12576453.
      View in: PubMed
    212. Han KR, Pantuck AJ, Belldegrun AS. Basic biology and clinical behavior of renal cell carcinoma. Cancer Treat Res. 2003; 116:69-89. PMID: 14650826.
      View in: PubMed
    213. Pantuck AJ, Zisman A, Belldegrun AS. Urologic oncology: extraordinary opportunities for discovery: highlights from the 2nd annual winter meeting of the society of urologic oncology december 1-2, 2001, bethesda, MD. Rev Urol. 2003; 5(1):26-8. PMID: 16985614; PMCID: PMC1472992.
    214. Perry KT, Zisman A, Gritsch HA, Pantuck A, Schulam PG. Use of heparin and protamine sulfate during laparoscopic donor nephrectomy. Transplantation. 2002 Dec 27; 74(12):1700-2. PMID: 12499884.
      View in: PubMed
    215. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002 Dec 01; 20(23):4559-66. PMID: 12454113.
      View in: PubMed
    216. Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Pantuck A, Belldegrun A, Palotie A. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer. 2002 Sep 15; 95(6):1247-57. PMID: 12216092.
      View in: PubMed
    217. Zisman A, Chao DH, Pantuck AJ, Kim HJ, Wieder JA, Figlin RA, Said JW, Belldegrun AS. Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. J Urol. 2002 Sep; 168(3):950-5. PMID: 12187197.
      View in: PubMed
    218. Marks LS, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders FE, Pantuck AJ, Tyler VE. PC-SPES: herbal formulation for prostate cancer. Urology. 2002 Sep; 60(3):369-75; discussion 376-7. PMID: 12350462.
      View in: PubMed
    219. Zisman A, Pantuck AJ, Chao DH, Wieder JA, Dorey F, Said JW, Kernion JB, Figlin R, Belldegrun AS. Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? J Urol. 2002 Sep; 168(3):962-7. PMID: 12187200.
      View in: PubMed
    220. Pantuck AJ, Berger F, Zisman A, Nguyen D, Tso CL, Matherly J, Gambhir SS, Belldegrun AS. CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. J Urol. 2002 Sep; 168(3):1193-8. PMID: 12187266.
      View in: PubMed
    221. Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control. 2002 Jul-Aug; 9(4):335-42. PMID: 12228759.
      View in: PubMed
    222. Pantuck AJ, Matherly J, Zisman A, Nguyen D, Berger F, Gambhir SS, Black ME, Belldegrun A, Wu L. Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. Hum Gene Ther. 2002 May 01; 13(7):777-89. PMID: 11975845.
      View in: PubMed
    223. Chao DH, Zisman A, Pantuck AJ, Freedland SJ, Said JW, Belldegrun AS. Changing concepts in the management of renal oncocytoma. Urology. 2002 May; 59(5):635-42. PMID: 11992832.
      View in: PubMed
    224. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici D, deKernion JB, Figlin RA, Belldegrun AS. Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol. 2002 Mar 01; 20(5):1368-74. PMID: 11870181.
      View in: PubMed
    225. Han KR, Pantuck AJ, Belldegrun AS. A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon. Curr Urol Rep. 2002 Feb; 3(1):11-2. PMID: 12084213.
      View in: PubMed
    226. Janzen N, Zisman A, Pantuck AJ, Perry K, Schulam P, Belldegrun AS. Minimally invasive ablative approaches in the treatment of renal cell carcinoma. Curr Urol Rep. 2002 Feb; 3(1):13-20. PMID: 12084214.
      View in: PubMed
    227. Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, Figlin RA, Belldegrun AS. Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol. 2002 Jan; 167(1):71-4. PMID: 11743278.
      View in: PubMed
    228. Han KR, Pantuck AJ, Belldegrun AS, Rao JY. Tumor markers for the early detection of bladder cancer. Front Biosci. 2002 Jan 01; 7:e19-26. PMID: 11779696.
      View in: PubMed
    229. Pantuck AJ, Zisman A, Cohen J, Belldegrun A. Cryosurgical ablation of renal tumors using 1.5-millimeter, ultrathin cryoprobes. Urology. 2002 Jan; 59(1):130-3. PMID: 11796298.
      View in: PubMed
    230. Perry K, Zisman A, Pantuck AJ, Janzen N, Schulam P, Belldegrun AS. Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Rev Urol. 2002; 4(3):103-11. PMID: 16985666; PMCID: PMC1475990.
    231. Pantuck AJ, Zisman A, Belldegrun A. Gene and immune therapy for renal cell carcinoma. Int J Urol. 2001 Jul; 8(7):S1-4. PMID: 11442668.
      View in: PubMed
    232. Angiographic management of pseudoaneurysm and arteriocalyceal fistula following blunt trauma: case report and review of the literature. Can J Urol. 1998 Dec; 5(5):654-657. PMID: 11319042.
      View in: PubMed
    233. Pantuck AJ, Fleisher MH, Barone JG. Genital hair strangulation in an uncircumcised boy. Can J Urol. 1997 Dec; 4(4):455. PMID: 12735813.
      View in: PubMed
    Allan's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _